openPR Logo
Press release

Huntington's Disease Pipeline Drugs Report 2025: Unveiling the Future of Therapeutics with DelveInsight's Expert Market and Pipeline Intelligence

09-30-2025 08:06 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Huntington's Disease Pipeline Drugs Report 2025: Unveiling

DelveInsight's "Huntington's Disease Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Huntington's Disease pipeline landscape. It covers the Huntington's Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Huntington's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Huntington's Disease Treatment Drugs @ Huntington's Disease Pipeline Outlook Report [https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Huntington's Disease Pipeline Report

* On 19 September 2025, Azidus Brasil conducted a phase II dose-response study in which participants with HD will receive three intravenous injections of the investigational product or placebo (one every month for three months) a total of three cycles. The subjects will be randomized in 2: 2: 1 ratio for the groups G1: lower dose (1x10^6 cells/weight range), G2: higher dose (2x10^6 cells/weight range), or G3: placebo.
* On 18 September 2025, Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) conducted a study consists of 2 parts: Dose-Finding Part and Expansion Part; each part consists of 3 phases: Screening Phase (8 weeks, with extension to 12 weeks to accommodate scheduling if needed), Treatment and Initial Follow-Up Phase (52 weeks) and Long-Term Follow-Up Phase (4 years). In the Dose-Finding Part, 2 dose titers will be tested in 3-6 subjects in each cohort. Once a dose is selected based on Dose-Limiting Toxicities, an additional 6 subjects will be enrolled into the Dose Expansion Part.
* On 15 September 2025, Supernus Pharmaceuticals Inc . organized a study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
* DelveInsight's Huntington's Disease pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Huntington's Disease treatment.
* The leading Huntington's Disease Companies such as Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG Bio, and others.
* Promising Huntington's Disease Pipeline Therapies such as Dimebon, Pridopidine, SAGE-718, Tominersen 60 mg, AB-1001, ISIS 443139 10 mg, ER2001 injection, and others.

Discover groundbreaking developments in Huntington's Disease therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Huntington's Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Huntington's Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Huntington's Disease Pipeline Report also highlights the unmet needs with respect to the Huntington's Disease.

Huntington's Disease Overview

Huntington's disease is a genetic, progressive, neurodegenerative disorder characterized by the gradual development of involuntary muscle movements affecting the hands, feet, face, and trunk and progressive deterioration of cognitive processes and memory (dementia). This disease causes changes in the central area of the brain, which affect movement, mood and thinking skills. Symptoms of Huntington's disease usually develop between ages 30 and 50, but they can appear as early as age 2 or as late as 80.

Huntington's Disease Emerging Drugs Profile

* RG6042: Hoffmann-La Roche

Tominersen (ASO-HTT, RG6042) is an antisense drug in development for the treatment of Huntington's disease. Tominersen is designed to reduce the production of all forms of the huntingtin (HTT) protein, which in its mutated variant (mHTT) is responsible for Huntington's disease. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Huntington's disease.

* PTC518: PTC Therapeutics

PTC518, a small molecule that can be taken orally, reduces the production of the mutated Huntingtin protein that leads to injury and death of the neuron, which results in disease progression. The orally bioavailable small molecule penetrates the blood brain barrier, is selective, titratable, and not effluxed. Currently the drug is in Phase II stage of its clinical trial for the treatment of Huntington's disease.

* ALN-HTT02: Alnylam Pharmaceuticals

ALN-HTT02 is an innovative therapeutic approach for Huntington's disease developed by Alnylam Pharmaceuticals. This drug is a small interfering RNA (siRNA) designed to reduce the production of the huntingtin protein, which is implicated in the disease's pathology. It works by targeting a specific region of the HTT gene's messenger RNA (mRNA), promoting its degradation and thereby preventing the synthesis of both normal and mutant huntingtin proteins. Administered via intrathecal injection. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Huntington's disease.

Stay informed about the Huntington's Disease pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Huntington's Disease Unmet Needs [https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Huntington's Disease Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Huntington's Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Huntington's Disease Treatment.
* Huntington's Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Huntington's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Huntington's Disease market

Huntington's Disease Companies

Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG Bio and others.

Huntington's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Huntington's Disease Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Transform your understanding of the Huntington's Disease Pipeline! See the latest progress in drug development and clinical research @ Huntington's Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Huntington's Disease Pipeline Report

* Coverage- Global
* Huntington's Disease Companies- Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG Bio and others.
* Huntington's Disease Pipeline Therapies- Dimebon, Pridopidine, SAGE-718, Tominersen 60 mg, AB-1001, ISIS 443139 10 mg, ER2001 injection, and others.
* Huntington's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Huntington's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Genetic Disorders Research-Access the Full Huntington's Disease Pipeline Analysis Today! @ Huntington's Disease Drugs and Companies [https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Huntington's Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Huntington's Disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* RG6042: Hoffmann-La Roche
* Mid Stage Products (Phase II)
* PTC518: PTC Therapeutics
* Early Stage Products (Phase I)
* ALN-HTT02: Alnylam Pharmaceuticals
* Mid Stage Products (Phase II)
* Preclinical Stage Products
* Drug Name: Company Name
* Inactive Products
* Huntington's Disease - Collaborations Assessment- Licensing / Partnering / Funding
* Huntington's Disease - Unmet Needs
* Huntington's Disease - Market Drivers and Barriers
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=huntingtons-disease-pipeline-drugs-report-2025-unveiling-the-future-of-therapeutics-with-delveinsights-expert-market-and-pipeline-intelligence]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/huntingtons-disease-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Huntington's Disease Pipeline Drugs Report 2025: Unveiling the Future of Therapeutics with DelveInsight's Expert Market and Pipeline Intelligence here

News-ID: 4204550 • Views:

More Releases from ABNewswire

Enhance Home Interiors with Quality Skirting Boards
Enhance Home Interiors with Quality Skirting Boards
For those looking to upgrade their interiors, investing in quality skirting boards is a simple yet effective way to transform a room. From protecting walls to enhancing aesthetics, skirting boards play a crucial role in creating polished, sophisticated, and functional living spaces. In modern interior design, small details can make a significant impact on the overall look and feel of a home. One such detail that combines functionality and aesthetic appeal
Experience the Ultimate Adventure at a Costa Rica Surf Camp
Experience the Ultimate Adventure at a Costa Rica Surf Camp
For those seeking a mix of thrill, relaxation, and cultural exploration, a Costa Rica surf camp offers an unparalleled experience. It's more than learning to surf-it's about connecting with nature, discovering new skills, and creating lifelong friendships. Whether it's your first time on a board or you're looking to refine your technique, Costa Rica's surf camps promise an adventure you won't soon forget. Costa Rica, known for its lush rainforests, stunning
Diffuse Large B Cell Lymphoma Pipeline Drugs Report 2025: Tracking Novel Therapies, Competitive Scenarios, and R&D Innovations Across Key Indications
Diffuse Large B Cell Lymphoma Pipeline Drugs Report 2025: Tracking Novel Therapi …
DelveInsight's "Diffuse Large B Cell Lymphoma Pipeline Insight 2025" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Diffuse Large B Cell Lymphoma pipeline landscape. It covers the Diffuse Large B Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further
DHODH Inhibitor Pipeline Drugs Report 2025: Comprehensive Analysis of Drug Development, Clinical Trials, and Strategic Industry Outlook
DHODH Inhibitor Pipeline Drugs Report 2025: Comprehensive Analysis of Drug Devel …
DelveInsight's "DHODH Inhibitor Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the DHODH Inhibitor pipeline landscape. It covers the DHODH Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the DHODH Inhibitor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious about the latest updates

All 5 Releases


More Releases for Huntington

AC Company in Huntington Upgrades Emergency Response Capabilities
As temperatures climb and air conditioners are pushed to their limits, many systems begin to fail under strain. Residents searching for a dependable ac company near me [https://summersphc.com/huntington/] in Huntington, IN, may notice faster response times and improved service delivery this summer. That's because Summers Plumbing Heating & Cooling has invested in enhancing its emergency HVAC response systems to meet the rising demand for rapid cooling solutions during heatwaves and mechanical
Reliable AC Installation Now Available for Huntington Homeowners
Whether you're upgrading from an outdated unit or installing a brand-new system, having a team that understands your specific needs is key. When temperatures rise and older systems falter, many homeowners start looking for AC installation near me [https://www.google.com/search?ac+installation+near+me&kgmid=/g/11tp8xn78c] to find the right solution for reliable cooling. In Huntington, a trusted name now offers convenient and professional service that makes the process easier than ever. With its long-standing reputation and customer-first
Maycon Construction Services: Premier Roofing Solutions in Huntington
Image: https://www.globalnewslines.com/uploads/2025/01/1735918960.jpg Huntington, NY - Maycon Construction Services is revolutionizing roofing services in Huntington with a commitment to quality, durability, and customer satisfaction. Specializing in Roof Repair Huntington [https://www.google.com/maps?cid=4993935758546148342], the company ensures homes and businesses are protected from leaks, weather damage, and structural issues. The team at Maycon Construction Services employs state-of-the-art techniques and premium materials to deliver lasting results. Their Roof Replacement Huntington [https://www.google.com/maps/place/Maycon+Construction+Services/@38.4112395,-82.36617,17z/data=!3m1!4b1!4m6!3m5!1s0x8846079778fdc4b5:0x454e061d07439bf6!8m2!3d38.4112395!4d-82.36617!16s%2Fg%2F11sqq7wlm7?authuser=0&hl=en&entry=ttu&g_ep=EgoyMDI0MTIwOC4wIKXMDSoASAFQAw%3D%3D] services are designed to provide an upgrade
SCHOOL OF ROCK HUNTINGTON READY TO ROCK N’ ROLL
Huntington, NY (November 17, 2016) – School of Rock, the leader in performance-based music education, announces the opening of its newest school in Huntington, New York, located at 145 East Main Street, Huntington, New York 11743. Opening on November 19, the school will host a party from 11 a.m. to 4 p.m., featuring live music from School of Rock students. In addition to the opening party, School of Rock Huntington
Huntington Beach Real Estate Agent Launches Luxury Home Buying Experience
The Malakai Sparks Group, a Huntington Beach, California-based realty agency spearheaded by president and real estate expert Malakai Sparks, announced the launch of its Huntington Beach Home Buying Experience service, which encompasses “curated experiences” from the entire Malakai Sparks Group team. Designed for the purpose of allowing prospective buyers to take in all Huntington Beach has to offer prior to purchasing a home – while making sure the area is
Gershow Recycling of Huntington Hosts Customer Appreciation Day
On August 24, Gershow Recycling hosted its Customer Appreciation Day at its Huntington Station facility. Those in attendance received giveaways, enjoyed food, games and the chance to win raffle prizes provided by Gershow and WBAB Radio (102.3 FM), which also provided music for the event. Gershow has eight locations in Brooklyn, New Hyde Park, Valley Stream, Freeport, Lindenhurst, Huntington Station, Bay Shore and Medford. For more information, call (631) 289-6188